CEO of Alnylam Pharmaceuticals Inc (30-Year Financial, Insider Trades) John Maraganore (insider trades) sold 34,765 shares of ALNY on 02/20/2020 at an average price of $131.85 a share. The total sale was $4.6 million.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes. Alnylam Pharmaceuticals Inc has a market cap of $14.75 billion; its shares were traded at around $131.03 with and P/S ratio of 65.06. GuruFocus has detected 2 severe warning signs with Alnylam Pharmaceuticals Inc. .
CEO Recent Trades:
- CEO John Maraganore sold 34,765 shares of ALNY stock on 02/20/2020 at the average price of $131.85. The price of the stock has decreased by 0.62% since.
Directors and Officers Recent Trades:
- Director Phillip A Sharp sold 30,000 shares of ALNY stock on 02/12/2020 at the average price of $130. The price of the stock has increased by 0.79% since.
- Director Steven M Paul sold 30,000 shares of ALNY stock on 02/10/2020 at the average price of $130. The price of the stock has increased by 0.79% since.
- EVP, Chief Legal Officer Laurie Keating sold 10,000 shares of ALNY stock on 02/10/2020 at the average price of $129. The price of the stock has increased by 1.57% since.
- COO Yvonne Greenstreet sold 16,142 shares of ALNY stock on 02/10/2020 at the average price of $127.64. The price of the stock has increased by 2.66% since.
- President, R&D Akshay Vaishnaw sold 23,708 shares of ALNY stock on 02/07/2020 at the average price of $125. The price of the stock has increased by 4.82% since.
For the complete insider trading history of ALNY, click here
.
